Drug safety test halted: how liver health changes medication

NCT ID NCT05126329

Summary

This study aimed to understand how liver function affects the processing of the breast cancer drug amcenestrant. It involved 13 female participants, some with mild to moderate liver impairment and others with normal liver function, who received a single dose. The main goal was to measure drug levels in the blood to see if liver problems change how the body handles the medication.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC FUNCTION ABNORMAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site Number :2760001

    Kiel, 24105, Germany

  • Investigational Site Number :4100001

    Seoul, Seoul-teukbyeolsi, 03080, South Korea

  • Investigational site number :4100002

    Cheongju-si, 28644, South Korea

Conditions

Explore the condition pages connected to this study.